[go: up one dir, main page]

SI1581235T1 - Uporaba spongozin (2-metoksiadenozeina) za zdravljenje bolečine, zlasti hiperalgezije - Google Patents

Uporaba spongozin (2-metoksiadenozeina) za zdravljenje bolečine, zlasti hiperalgezije

Info

Publication number
SI1581235T1
SI1581235T1 SI200331633T SI200331633T SI1581235T1 SI 1581235 T1 SI1581235 T1 SI 1581235T1 SI 200331633 T SI200331633 T SI 200331633T SI 200331633 T SI200331633 T SI 200331633T SI 1581235 T1 SI1581235 T1 SI 1581235T1
Authority
SI
Slovenia
Prior art keywords
spongosine
treatment
pain
methoxyadenosein
hyperalgesia
Prior art date
Application number
SI200331633T
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Publication of SI1581235T1 publication Critical patent/SI1581235T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200331633T 2002-12-09 2003-12-09 Uporaba spongozin (2-metoksiadenozeina) za zdravljenje bolečine, zlasti hiperalgezije SI1581235T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0228723.3A GB0228723D0 (en) 2002-12-09 2002-12-09 Treatment of pain
EP03780370A EP1581235B1 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia
PCT/GB2003/005379 WO2004052377A1 (en) 2002-12-09 2003-12-09 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia

Publications (1)

Publication Number Publication Date
SI1581235T1 true SI1581235T1 (sl) 2009-10-31

Family

ID=9949371

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331633T SI1581235T1 (sl) 2002-12-09 2003-12-09 Uporaba spongozin (2-metoksiadenozeina) za zdravljenje bolečine, zlasti hiperalgezije

Country Status (18)

Country Link
US (2) US8252766B2 (sl)
EP (1) EP1581235B1 (sl)
JP (2) JP4836454B2 (sl)
KR (1) KR101122495B1 (sl)
CN (2) CN101264097B (sl)
AT (1) ATE430572T1 (sl)
AU (1) AU2003288451B2 (sl)
CA (1) CA2507918A1 (sl)
CY (1) CY1109229T1 (sl)
DE (1) DE60327557D1 (sl)
DK (1) DK1581235T3 (sl)
ES (1) ES2326532T3 (sl)
GB (2) GB0228723D0 (sl)
NO (1) NO20053042L (sl)
NZ (1) NZ540353A (sl)
PT (1) PT1581235E (sl)
SI (1) SI1581235T1 (sl)
WO (1) WO2004052377A1 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
SG144146A1 (en) * 2004-03-05 2008-07-29 Cambridge Biotechnology Ltd Adenosine receptor agonists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AU2007263727A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor
AU2007263726A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
NZ573308A (en) * 2006-06-27 2012-02-24 Biovitrum Ab Publ Adenosine derivatives for the treatment of pain
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
US8221791B1 (en) 2008-12-10 2012-07-17 University Of Central Florida Research Foundation, Inc. Silica-based antibacterial and antifungal nanoformulation
SG177557A1 (en) * 2009-07-09 2012-02-28 Cbt Dev Ltd Combined preparation for use as a medicament
US20130123208A1 (en) * 2010-05-12 2013-05-16 The Regents of the University of Colorado, a body corporation Method of treating multiple sclerosis with adenosine receptor agonists
EP2631345B1 (en) * 2012-02-27 2019-09-04 Electrolux Home Products Corporation N.V. Washing tub unit and washing machine
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
CN108697701B (zh) * 2016-02-04 2021-10-26 约翰霍普金斯大学 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4861498A (sl) 1971-12-01 1973-08-28
BE792155A (fr) 1971-12-01 1973-05-30 Takeda Chemical Industries Ltd Nouveaux derives de l'adenosine et leur procede de production
DE2359536C2 (de) * 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5549594B2 (sl) 1972-12-08 1980-12-12
JPS5461194A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
JPS5461195A (en) 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
US4705758A (en) * 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5104859A (en) * 1985-09-24 1992-04-14 Solimedco Aktiebolag Continuous administration of adenosine to reduce pulmonary vascular resistance
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US6180616B1 (en) * 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
AU6516494A (en) 1993-04-15 1994-11-08 New York University Adenosine receptor agonists for the promotion of wound healing
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
SE9401499D0 (sv) 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
HUT75338A (en) 1994-05-10 1997-05-28 Sandoz Ag Adenosine derivatives, their preparation and use, and pharmaceutical preparations containing them
US5596094A (en) * 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
EP0983768A1 (en) 1997-05-23 2000-03-08 Nippon Shinyaku Co., Ltd. Medicinal composition for prevention or treatment of hepatopathy
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
WO1999034804A1 (en) 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation A2a adenosine receptor agonists
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2551169A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
SG144146A1 (en) 2004-03-05 2008-07-29 Cambridge Biotechnology Ltd Adenosine receptor agonists
US8407664B2 (en) 2005-12-30 2013-03-26 Sap Ag Software model business objects

Also Published As

Publication number Publication date
ES2326532T3 (es) 2009-10-14
GB2396108A (en) 2004-06-16
KR101122495B1 (ko) 2012-03-15
US8252766B2 (en) 2012-08-28
AU2003288451B2 (en) 2009-06-04
GB0328548D0 (en) 2004-01-14
JP2006514638A (ja) 2006-05-11
EP1581235B1 (en) 2009-05-06
CY1109229T1 (el) 2013-09-04
ATE430572T1 (de) 2009-05-15
CN101264097B (zh) 2011-10-05
GB0228723D0 (en) 2003-01-15
PT1581235E (pt) 2009-07-07
WO2004052377A1 (en) 2004-06-24
KR20050089815A (ko) 2005-09-08
CN1723026A (zh) 2006-01-18
AU2003288451A1 (en) 2004-06-30
CN101264097A (zh) 2008-09-17
GB2396108B (en) 2005-08-03
CA2507918A1 (en) 2004-06-24
CN100471503C (zh) 2009-03-25
EP1581235A1 (en) 2005-10-05
DE60327557D1 (de) 2009-06-18
JP4836454B2 (ja) 2011-12-14
US20110184065A1 (en) 2011-07-28
NO20053042L (no) 2005-06-21
HK1086186A1 (zh) 2006-09-15
NZ540353A (en) 2006-11-30
JP2011132229A (ja) 2011-07-07
DK1581235T3 (da) 2009-08-31
US20070010475A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
PT1581235E (pt) Utilização de espongosina (2-metoxiadenoseína) para o tratamento de dor, em particular hiperalgesia
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
WO2005023179A3 (en) Combination methods of treating cancer
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
ECSP034922A (es) Pirrolopirimidinas
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
GB0305149D0 (en) Compounds for the treatment of pain
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
AU2483000A (en) Treatment of asthma with mek inhibitors
MY151032A (en) Treatment of tnf? related disorders
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
NZ545935A (en) Method of treating cancer with HDAC inhibitors
WO2004010937A3 (en) Method of treating cancer
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
IL172773A (en) Formulations for the treatment of arthritis conditions
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2008060381A3 (en) Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
WO2005041885A3 (en) Compositions and methods for treating, preventing, reversing and inhibiting pain